Dear Doctor Letter (Rote-Hand-Brief) on Gilenya® (fingolimod): Hemophagocytic syndrome
2013.11.18
Active substance: fingolimod
The company Novartis Pharma GmbH is circulating information on reports of 2 cases of a hemophagocytic syndrome (HPS) leading to the deaths of patients with relapsing-remitting multiple sclerosis treated with fingolimod.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN